Actively Recruiting
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Led by Teclison Ltd. · Updated on 2026-04-16
110
Participants Needed
3
Research Sites
332 weeks
Total Duration
On this page
Sponsors
T
Teclison Ltd.
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
CONDITIONS
Official Title
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
- mCRC progressed on at least two lines of standard chemotherapy; or
- NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
- Measurable disease
- ECOG 0-1
- At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
- Adequate organ function
You will not qualify if you...
- Prior organ transplantation
- Liver metastasis more than 50%
- Oxygen saturation less than 92% in room air
- Prior autoimmune disorder
- CNS metastasis
- Major GI bleeding in the last 2 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of California, Irvine Medical Center
Orange, California, United States, 92868
Actively Recruiting
2
China Medical University Hsinchu Hospital
Hsinchu, Taiwan
Actively Recruiting
3
Chung Shan Medical University Hospital
Taichung, Taiwan
Actively Recruiting
Research Team
R
Ray Lee, MD. PhD.
CONTACT
C
Chiwei Lu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here